Compounded semaglutide for weight loss

A plain-language guide to how compounded semaglutide works, who it is appropriate for, and what to expect during treatment.

What is semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a class of medications that mimic a hormone the gut releases after meals. By acting on GLP-1 receptors in the brain, gut, and pancreas, semaglutide reduces appetite, slows stomach emptying, and improves how the body handles blood sugar. It is the active ingredient in branded products such as Ozempic and Wegovy. Compounded semaglutide contains the same active ingredient and is prepared by licensed U.S. compounding pharmacies.

How does semaglutide work for weight loss?

Semaglutide influences three biological systems that drive weight gain and difficulty losing weight:

• Appetite signaling. It activates GLP-1 receptors in the hypothalamus, quieting the constant background "food noise" that drives snacking and oversized meals.
• Gastric emptying. It slows the rate food leaves the stomach, so meals feel satisfying for longer.
• Insulin and glucose regulation. It increases glucose-dependent insulin release and lowers post-meal blood sugar swings, reducing the energy crashes that trigger cravings.

The result is a lower daily calorie intake without conscious restriction — most members report eating noticeably less without willpower fatigue.

Who is compounded semaglutide for?

Compounded semaglutide may be appropriate for adults who:

• Have a body mass index (BMI) of 30 or higher, or 27 or higher with at least one weight-related condition (such as type 2 diabetes, hypertension, or obstructive sleep apnea)
• Have not achieved target weight loss with diet, exercise, and lifestyle changes alone
• Do not have contraindications such as a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia type 2 (MEN 2), pancreatitis, severe gastrointestinal disease, or active eating disorders
• Are not pregnant, planning pregnancy, or breastfeeding

Eligibility is determined only after a licensed clinician in our third-party provider network reviews your medical intake.

How is semaglutide dosed?

Dosing is titrated upward over several months to allow your body to adjust and minimize side effects. A typical schedule:

• Weeks 1–4: 0.25 mg once weekly
• Weeks 5–8: 0.5 mg once weekly
• Weeks 9–12: 1.0 mg once weekly
• Week 13+: 1.7 mg, then 2.4 mg once weekly as tolerated

Your clinician adjusts the schedule based on your response, side effects, and goals. Some members reach their target weight at a lower dose and stay there.

Expected results

In clinical trials of branded semaglutide for chronic weight management, adults lost on average 14.9% of their body weight at 68 weeks on the 2.4 mg dose, compared to 2.4% in the placebo group. Most members notice reduced food noise within 7–14 days and begin losing weight by week 4. Individual results depend on dose, adherence, nutrition, activity, and underlying biology.

Common side effects

The most frequent side effects, especially during dose escalation, are:

• Nausea (mild to moderate, usually resolves within 1–2 weeks of each new dose)
• Constipation or diarrhea
• Fatigue
• Reflux or burping
• Decreased appetite (intended)

Less common but serious risks include pancreatitis, gallbladder disease, kidney issues, and — rarely — thyroid C-cell tumors. GLP-1 medications carry a boxed warning for medullary thyroid carcinoma. Your clinician will review the full risk profile during your evaluation.

Safety and contraindications

Do not use semaglutide if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2), a history of pancreatitis, or hypersensitivity to semaglutide. It is not used during pregnancy or breastfeeding.

Frequently asked questions

Related reading

References & sources